Alcami has bolstered its sterile fill-finish capabilities with the acquisition of TriPharm Services. The deal comes a new state-of-the-art sterile fill-finish manufacturing center located near Research Triangle Park, NC and follows the recently announced $17 million expansion of Alcami’s sterile fill-finish facility in Charleston, SC.
 
In conjunction with this acquisition, funds affiliated with Madison Dearborn Partners, Alcami’s existing majority owner, made an additional equity investment to fund Alcami’s growth plan and the former majority owner of TriPharm, Ampersand Capital Partners, rolled a portion of its TriPharm ownership interest into an ownership interest in Alcami.
 
TriPharm’s facility bolsters Alcami’s existing sterile fill-finish business, adding new prefilled syringe capabilities and isolator technology, while also providing incremental flexible sterile fill-finish and lyophilization capacity to meet growing industry demand. TriPharm’s new manufacturing facility is expected to be operational beginning in the second half of 2020.
 
“Our combination with TriPharm is an important next step in the execution of Alcami’s strategy to focus investments across our network to better serve rapidly growing specialized market segments,” said George Van Kula, interim chief executive officer, Alcami. “TriPharm expands our existing capabilities and provides additional equipment lines that will allow us to better serve the fast-developing biologics market segment.”
 
“As drug makers increasingly shift their focus toward more specialized, targeted therapeutics, and current injectable drug shortages hamper patient care, sterile fill-finish operations at proper scale are highly valued,” said Patrick Walsh, chief executive officer, TriPharm. “Our Research Triangle Park facility is designed to address this highly specialized industry demand.